R207
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 93
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.400
- DNA_REPAIR+0.310
- MYC_TARGETS_V1+0.240
- E2F_TARGETS+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.150
- G2M_CHECKPOINT+0.130
- CHOLESTEROL_HOMEOSTASIS+0.100
- PEROXISOME+0.100
- BILE_ACID_METABOLISM+0.090
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.520
- INFLAMMATORY_RESPONSE-0.510
- INTERFERON_GAMMA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.460
- INTERFERON_ALPHA_RESPONSE-0.460
- TNFA_SIGNALING_VIA_NFKB-0.430
- COMPLEMENT-0.370
- KRAS_SIGNALING_UP-0.340
- IL2_STAT5_SIGNALING-0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 63bab58e-1dfd-43df-8188-4b8d766913f3 | — | — | 0.888 |
| 2 | SRR2780123 | — | — | 0.871 |
| 3 | MDT-AP-1199 | Med | Medulloblastoma | 0.866 |
| 4 | TCGA-A8-A09C-01A-11R-A00Z-07 | — | B | 0.862 |
| 5 | X299bbf8b.babb.4be2.a190.5411dc005aae | — | cohortA1 | 0.851 |
| 6 | SRR12475107 | — | — | 0.848 |
| 7 | MNG392 | — | — | 0.845 |
| 8 | R115 | — | — | 0.844 |
| 9 | MDT-AP-0421 | Med | Medulloblastoma | 0.837 |
| 10 | TCGA-S3-AA12-01A-11R-A41B-07 | — | B | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.400 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.100 | Remibrutinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.060 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.050 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |